Healthcare

Sonic Healthcare runs a large international diagnostics network focused on pathology and imaging. The shares reflect caution, yet the business still shows resilient healthcare demand, renewed revenue growth, solid cash generation, and meaningful scale in several core markets.

Rhythm Pharmaceuticals sells a targeted treatment for rare genetic obesity and has been growing revenue quickly as diagnosis and market access expand. Its niche leadership and pipeline optionality make the company worth a closer look for long-term business analysis.

RadNet combines one of the largest outpatient imaging networks in the U.S. with an expanding radiology AI platform. Strong revenue momentum and exposure to growing screening demand make the company especially worth a closer look.

PTC Therapeutics is a rare-disease biotech with marketed products, partnership income, and a pipeline that can materially change its scale. The appeal comes from strong recent revenue expansion and a growing commercial base that could support a more durable business model.

PACS Group operates skilled nursing and post-acute care facilities across the U.S. Rapid expansion, rising free cash flow, and improving margins have made it a notable player in a fragmented market, with future progress closely tied to execution and balance-sheet improvement.

Oruka Therapeutics is a clinical-stage biotech targeting inflammatory skin diseases, with market attention centered on its psoriasis pipeline. A debt-light balance sheet and focused strategy stand out, while future value hinges on turning heavy R&D spending into compelling clinical results.

Merit Medical makes the disposable tools used in many minimally invasive procedures. Revenue, margins, and cash flow have all moved up, giving the company an increasingly stronger profile in medtech niches tied to long-term healthcare demand.